Claims for Patent: 8,945,918

Summary for Patent: 8,945,918

Title:	Expression in insect cells of genes with overlapping open reading frames, methods and compositions therefor
Abstract:	The present teachings disclose nucleic acid cassettes for expressing in an insect cell a plurality of polypeptides encoded by a gene comprising overlapping open reading frames (ORFs). A cassette comprises, in 5\' to 3\' order, a) a first insect cell-operable promoter, b) a 5\' portion of a gene comprising a first ORF of the gene, c) an intron comprising a second insect cell-operable promoter, and d) a 3\' portion of the gene comprising at least one additional ORF. Vectors and insect cells comprising the cassettes are also disclosed, as well as methods for production of recombinant adeno-associated virus in insect cells using the cassettes.
Inventor(s):	Chen; Haifeng (Castro Valley, CA)
Assignee:	Virovek, Inc. (Hayward, CA)
Application Number:	12/297,958
Patent Claims:	1. A nucleic acid cassette for expressing in an insect cell a plurality of polypeptides encoded by a parvovirus capsid gene, the cassette comprising in 5' to 3' order: (i) a first insect cell operable promoter linked operably to a 5' portion of a first ORF of the parvovirus capsid gene, the first ORF comprising a translation initiation codon, (ii) an intron comprising a second insect cell operable promoter, the second promoter operably linked to a 5' portion of an at least one additional ORF of a parvovirus capsid gene, wherein the at least one additional ORF comprises at least one additional translation initiation codon and overlaps with the 3' portion of the first ORF. 2. A nucleic acid cassette in accordance with claim 1, wherein the first ORF is a VP1 ORF and the at least one additional ORF is a VP2/VP3 ORF. 3. A nucleic acid cassette for expressing in an insect cell a plurality of polypeptides encoded by a parvovirus Rep gene, the cassette comprising in 5' to 3' order: (i) a first insect cell operable promoter linked operably to a 5' portion of a first ORF of the parvovirus Rep gene, the first ORF comprising a translation initiation codon, (ii) an intron comprising a second insect cell operable promoter, the second promoter operably linked to a 5' portion of an at least one additional ORF of a parvovirus Rep gene, wherein the at least one additional ORF comprises at least one additional translation initiation codon and overlaps with the 3' portion of the first ORF. 4. A nucleic acid cassette for expressing in an insect cell a plurality of polypeptides encoded by a polyomavirus gene, the cassette comprising in 5' to 3' order: (i) a first insect cell operable promoter linked operably to a 5' portion of a first ORF of a polyomavirus capsid gene, the first ORF comprising a translation initiation codon, (ii) an intron comprising a second insect cell operable promoter, the second promoter operably linked to a 5' portion of an at least one additional ORF of a polyomavirus capsid gene, wherein the at least one additional ORF comprises at least one additional translation initiation codon and overlaps with the 3' portion of the first ORF. 5. A nucleic acid cassette in accordance with claim 1, 3 or 4, further comprising a polyadenylation signal situated 3' to the additional ORF in (ii). 6. A nucleic acid cassette in accordance with claim 1, 3 or 4, wherein each of the first insect cell-operable promoter and the second insect cell-operable promoter is independently selected from the group consisting of a p10 promoter and a polh promoter. 7. A nucleic acid cassette in accordance with claim 3, wherein the first ORF is a Rep 78/68 ORF and the at least one additional ORF is a Rep 52/40 ORF. 8. A nucleic acid cassette in accordance with claim 1, 3 or 4, wherein the first promoter is a p10 promoter and the second promoter is a polh promoter. 9. A nucleic acid cassette in accordance with claim 1, 3 or 4, wherein the first promoter is a first polh promoter and the second promoter is a second polh promoter. 10. A vector comprising the nucleic acid cassette of claim 1, 3 or 4. 11. A vector in accordance with claim 10, wherein the vector is selected from the group consisting of a plasmid, a virus and a combination thereof. 12. An isolated insect cell comprising the nucleic acid cassette of claim 1, 3 or 4. 13. An isolated insect cell comprising a first nucleic acid cassette of claim 1 and a second nucleic acid cassette, wherein the first nucleic acid cassette comprises a Cap gene comprising a VP1 ORF and a VP2/VP3 ORF and the second nucleic acid cassette comprises: (i) a first insect cell operable promoter linked operably to a 5' portion of a first ORF of the parvovirus Rep gene, the first ORF comprising a translation initiation codon, (ii) an intron comprising a second insect cell operable promoter, the second promoter operably linked to a 5' portion of an at least one additional ORF of a parvovirus Rep gene, wherein the at least one additional ORF comprises at least one additional translation initiation codon and overlaps with the 3' portion of the first ORF. 14. An isolated insect cell in accordance with claim 13, further comprising an additional nucleic acid cassette, the additional cassette comprising, in 5' to 3' order: a first inverted terminal repeat (ITR) of an adeno-associated virus; a mammalian cell-operable promoter; a transgene; a polyadenylation signal; and a second ITR of an AAV. 15. An insect cell in accordance with claim 14, wherein the transgene is a reporter gene encoding a polypeptide selected from the group consisting of a chloramphenicol acetyl transferase, a .beta.-galactosidase, a .beta.-glucoronidase, a renilla luciferase, a firefly luciferase, a green fluorescent protein (GFP), a red fluorescent protein (RFP) and an alkaline phosphatase. 16. An insect cell in accordance with claim 14, wherein the transgene comprises an ORF encoding a polypeptide selected from the group consisting of a polypeptide hormone, an interferon, a blood clotting factor, a vaccine and an erythropoietin. 17. An insect cell in accordance with claim 12, wherein the nucleic acid cassette is integrated into the genome of the insect cell. 18. An insect cell in accordance with claim 14, wherein at least one of the nucleic acid cassette and the additional nucleic acid cassette is integrated into the genome of the insect cell. 19. An insect cell in accordance with claim 12, wherein the cell is selected from the group consisting of a Trichoplusia ni BTI-Tn-5B1-4 cell, a Spodoptera frugiperda Sf9 cell and a Spodoptera frugiperda Sf21 cell. 20. A cell culture comprising: a plurality of insect cells of claim 12; and a culture medium. 21. A cell culture comprising: a plurality of insect cells of claim 14; and a culture medium comprising at least 10.sup.13 AAV genomes/liter. 22. A cell culture in accordance with claim 21, wherein the culture medium comprising at least 10.sup.13 AAV genomes/liter is a culture medium comprising at least 10.sup.14 AAV genomes/liter. 23. A nucleic acid comprising the cassette of claim 5, further comprising a second cassette, the second cassette comprising, in 5' to 3' order: a second polyadenylation signal; a 3' portion of a second gene comprising overlapping ORFs; a second intron comprising a third insect-operable promoter; a 5' portion of the second gene; and a fourth insect operable promoter. 24. A nucleic acid in accordance with claim 23, wherein the second cassette is in an anti-sense orientation relative to the first cassette. 25. A nucleic acid in accordance with claim 23, wherein the second cassette is in a sense orientation relative to the first cassette. 26. A nucleic acid in accordance with claim 23, wherein the first cassette comprises an AAV Rep gene comprising a Rep 78/68 ORF and a Rep 52/40 ORF and the second cassette comprises an AAV Cap gene comprising a VP1 ORF and a VP2/VP3 ORF.

Details for Patent 8,945,918

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2026-08-24
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2026-08-24
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2026-08-24